Search Medical Condition
Please enter condition
Please choose location from dropdown

Hermitage, Tennessee Clinical Trials

A listing of Hermitage, Tennessee clinical trials actively recruiting patient volunteers.

RESULTS

Found (24) clinical trials

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

Patients clinically suspected of NASH will be invited for a screening programme for inclusion in the study. Patients will be screened according to the inclusion and exclusion criteria. Clinical evaluation will be conducted for baseline characteristics and anthropometry measurements such as body weight and height. After clinical evaluations, all baseline ...

Phase

0.0 miles

Learn More »

A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.

Phase

0.0 miles

Learn More »

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

Semaglutide is a medicine studied in patients with non-alcoholic steatohepatitis (NASH), as it may improve liver damage. Participants will either get semaglutide or placebo (a dummy medicine) - which treatment participants get is decided by chance. The study will last for about 61 weeks in total. Participants will have 10 ...

Phase

0.0 miles

Learn More »

CLUSTER Trial for Outbreak Detection and Response

Despite the critical importance of identifying hospital-associated outbreaks as early as possible in order to limit their spread, there are currently no standardized methods for cluster detection. The CLUSTER Trial (Cluster Linkage Using Statistics to Trigger and Evaluate Response) will assess whether a statistically-based automated cluster detection method coupled with ...

Phase N/A

0.0 miles

Learn More »

A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.

This is a randomized, double-blind, placebo-controlled, study to evaluate the safety (including hepatic safety), tolerability and pharmacodynamic effects of two dose levels of MEDI0382 in obese subjects with non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH). The subjects will have biopsy-confirmed NAFLD/NASH with liver fibrosis stage F1, F2 or F3. Approximately ...

Phase

0.0 miles

Learn More »

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at Randomization and every four weeks from Week 4 through Week 52 and through End of Study period. The study includes a post-dosing study visit that will occur 4 weeks after the last dose of study drug. This ...

Phase

0.0 miles

Learn More »

The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

Phase

5.33 miles

Learn More »

A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice

This is a phase 3 randomized, multi-center, double-blind, placebo controlled, parallel group design study. This study is comprised of two phases: screening and treatment. The screening period is 24 hours, followed by the treatment phase of 15 3 days. During the treatment phase, subjects will be randomized to either test, ...

Phase

6.41 miles

Learn More »

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

This is a multicentre, randomized, double-blind, placebo controlled, parallel group study designed to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 1060 subjects will be ...

Phase

8.34 miles

Learn More »

TARGET Post-Approval Study

A maximum of 376 adult subjects with moderate to severe chronic, intractable, pain of the lower limbs due to CRPS types I and II will undergo a trial of the Axium Neurostimulator System across 40 study sites in the United States. Only subjects who report a 50% or greater reduction ...

Phase N/A

8.34 miles

Learn More »